The emergence of novel coronavirus (SARS-CoV-2) caused the Coronavirus Disease 2019 (COVID-19) pandemic in December 2019. Up to 28 August 2020, there were 165,887 cases and 7,169 deaths recorded. Twenty-seventh of August 2020 marks the all-time highest daily increase of COVID-19 case in Indonesia at 2,719. This pandemic is a great challenge for healthcare providers worldwide, as there was yet effective medication nor vaccine to cure the disease.

It is Universitas Indonesia’s interest as the leading medical university in Indonesia to contribute resolving the impact caused by COVID-19. Academic Health System Universitas Indonesia (AHS-UI) was founded in 2014 by the Minister of health, Minister of education, and Minister of higher education. AHS-UI is a collaborating platform between Faculties in Universitas Indonesia (Medicine, Dentistry, Public Health, Nursing, and Pharmacy) and Jakarta Provincial Government in the form of 9 public hospitals across Jakarta. Therefore, AHS-UI is a potential platform in combating COVID-19.

Such collaboration enables extensive cooperation for healthcare education, research, and community service, especially concerning COVID-19. Ongoing research includes stem cell research, plasma convalescence, radiological artificial intelligence (AI), and pharmaceutical research. Multicentre collaboration of research are conducted with favipirapir as COVID-19 treatment between hospitals in AHS-UI. These researches are supported by Jakarta’s Provincial Government and up until today the outcome especially concerning COVID-19 is promising. The positive outcome of these research hopefully can be implemented for educating health workers & community, thus ultimately help to combat COVID-19 disease in Indonesia.